Immunovia announces updated financial calendar

Rhea-AI Summary

Immunovia (IMMNOV: Nasdaq) updates its financial calendar for 2024, with key dates like the Annual Report on April 25, Q1 Report on April 25, Annual General Meeting on June 4, Q2 Report on August 22, and Q3 Report on November 14. The company aims to increase pancreatic cancer survival rates through early detection using blood-based testing. Immunovia collaborates with healthcare providers and experts to make its test available to high-risk individuals, estimating 1.8 million at risk in the USA. Shares of Immunovia (IMMNOV) are listed on Nasdaq Stockholm.

LUND, Sweden, March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq)  (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024.

Annual Report to be published	April 25, 2024
Q1 Report, 2024	April 25, 2024
Annual General Meeting	June 4, 2024
Q2 Report, 2024	August 22, 2024
Q3 Report, 2024	November 14, 2024

For more information, please contact:
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com 
+46 709 11 56 08 

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-announces-updated-financial-calendar,c3944595

The following files are available for download:

https://mb.cision.com/Main/13121/3944595/2664104.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/immunovia-announces-updated-financial-calendar-302086865.html

SOURCE Immunovia AB

FAQ

When will Immunovia publish its Annual Report for 2024?

Immunovia will publish its Annual Report for 2024 on April 25, 2024.

What is the mission of Immunovia?

Immunovia's mission is to increase survival rates for patients with pancreatic cancer through early detection.

Where are Immunovia's shares listed?

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

How many individuals in the USA are estimated to be at high risk for pancreatic cancer?

In the USA, Immunovia estimates that 1.8 million individuals are at high risk for pancreatic cancer.

Who can benefit from Immunovia's annual surveillance testing?

High-risk individuals for pancreatic cancer can benefit from Immunovia's annual surveillance testing.